Fluidigm Pays Life Tech $2M to Shield Itself from PCR-related Patent Litigation | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fluidigm has paid Life Technologies $2 million to shield itself from litigation related to Life Tech's PCR patents, some of which were the subject of lawsuits the two firms filed against each other in June.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.